---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-046867"
form_type: "8-K"
ticker: "OVID"
cik: "0001636651"
company_name: "Ovid Therapeutics Inc."
filed_at: "2024-11-12T23:59:59+00:00"
generated_at: "2026-05-30T01:58:32.964767+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Ovid Q3 net loss $14.0M ($0.20/share); cash $62.7M; pauses CCM Phase 2, advances OV329/OV350

## Summary
- Net loss of $14.0M ($0.20 per share) vs $11.3M in Q3 2023; royalty revenue $173K.
- Cash and marketable securities $62.7M; expected to fund operations into H2 2026.
- Phase 1 MAD study of OV329 progressing; plans to add cohorts for higher dosing; topline data in 2025.
- Regulatory application for Phase 1 trial of OV350 (KCC2 direct activator) expected in Q4 2024; first-in-human Q1 2025.
- Pause of Phase 2 study of OV888/GV101 in CCM to incorporate competitor trial insights; ROCK2 programs continue.

## SEC filing metadata
- accession: 0001628280-24-046867
- form_type: 8-K
- ticker: OVID
- cik: 0001636651
- company_name: Ovid Therapeutics Inc.
- filed_at: 2024-11-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1636651/000162828024046867/0001628280-24-046867-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1636651/000162828024046867/ovid-20241112.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-046867
- JSON: https://secwatch.observer/filing/0001628280-24-046867.json
- Plain text: https://secwatch.observer/filing/0001628280-24-046867.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.